BRIEF-Denali Therapeutics Announces Primary Analysis & Long-Term Follow-Up Of Phase 1/2 Study In Hunter Syndrome With Tividenofusp Alfa

Reuters

07 Feb

BRIEF-Denali <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Primary Analysis & Long-Term Follow-Up Of Phase 1/2 Study In Hunter Syndrome With Tividenofusp Alfa

Feb 6 (Reuters) - Denali Therapeutics Inc DNLI.O:

DENALI THERAPEUTICS ANNOUNCES PRIMARY ANALYSIS AND LONG-TERM FOLLOW-UP OF PHASE 1/2 STUDY IN HUNTER SYNDROME (MPS II) WITH TIVIDENOFUSP ALFA
DENALI THERAPEUTICS: TIVIDENOFUSP ALFA REGULATORY SUBMISSION FOR ACCELERATED APPROVAL PLANNED FOR EARLY 2025
DENALI THERAPEUTICS: TIVIDENOFUSP ALFA U.S. LAUNCH PREPARATION ONGOING TO DELIVER TIVIDENOFUSP ALFA TO FAMILIES WITH MPS II IN LATE 2025 OR EARLY 2026
DENALI THERAPEUTICS INC: LONG-TERM SAFETY DATA DEMONSTRATE THAT TIVIDENOFUSP ALFA WAS GENERALLY WELL TOLERATED

Source text: ID:nGNX21hgts

Further company coverage: DNLI.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2509206746"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2509206746\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2509206746?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-07 00:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2509206746","market":"us","top_or_hot":-1,"title":"BRIEF-Denali Therapeutics Announces Primary Analysis & Long-Term Follow-Up Of Phase 1/2 Study In Hunter Syndrome With Tividenofusp Alfa","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Denali <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Primary Analysis & Long-Term Follow-Up Of Phase 1/2 Study In Hunter Syndrome With Tividenofusp Alfa</title></head><body><p><span>Feb 6 (Reuters)</span><span> - </span>Denali Therapeutics Inc <span>DNLI.O</span>:</p><ul><li><p>DENALI THERAPEUTICS ANNOUNCES PRIMARY ANALYSIS AND LONG-TERM FOLLOW-UP OF PHASE 1/2 STUDY IN HUNTER SYNDROME (MPS II) WITH TIVIDENOFUSP <a href=\"https://laohu8.com/S/ALFA.AU\">ALFA</a></p></li><li><p>DENALI THERAPEUTICS: TIVIDENOFUSP ALFA REGULATORY SUBMISSION FOR ACCELERATED APPROVAL PLANNED FOR EARLY 2025</p></li><li><p>DENALI THERAPEUTICS: TIVIDENOFUSP ALFA U.S. LAUNCH PREPARATION ONGOING TO DELIVER TIVIDENOFUSP ALFA TO FAMILIES WITH MPS II IN LATE 2025 OR EARLY 2026</p></li><li><p>DENALI THERAPEUTICS INC: LONG-TERM SAFETY DATA  DEMONSTRATE THAT TIVIDENOFUSP ALFA WAS GENERALLY WELL TOLERATED</p></li></ul><p>Source text: <span>ID:nGNX21hgts</span></p><p>Further company coverage: <span>DNLI.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>BRIEF-Denali Therapeutics Announces Primary Analysis & Long-Term Follow-Up Of Phase 1/2 Study In Hunter Syndrome With Tividenofusp Alfa</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Denali Therapeutics Announces Primary Analysis & Long-Term Follow-Up Of Phase 1/2 Study In Hunter Syndrome With Tividenofusp Alfa\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-02-07 00:45</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<title>BRIEF-Denali <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Primary Analysis & Long-Term Follow-Up Of Phase 1/2 Study In Hunter Syndrome With Tividenofusp Alfa</title><p><span>Feb 6 (Reuters)</span><span> - </span>Denali Therapeutics Inc <span>DNLI.O</span>:</p><ul><li><p>DENALI THERAPEUTICS ANNOUNCES PRIMARY ANALYSIS AND LONG-TERM FOLLOW-UP OF PHASE 1/2 STUDY IN HUNTER SYNDROME (MPS II) WITH TIVIDENOFUSP <a href=\"https://laohu8.com/S/ALFA.AU\">ALFA</a></p></li><li><p>DENALI THERAPEUTICS: TIVIDENOFUSP ALFA REGULATORY SUBMISSION FOR ACCELERATED APPROVAL PLANNED FOR EARLY 2025</p></li><li><p>DENALI THERAPEUTICS: TIVIDENOFUSP ALFA U.S. LAUNCH PREPARATION ONGOING TO DELIVER TIVIDENOFUSP ALFA TO FAMILIES WITH MPS II IN LATE 2025 OR EARLY 2026</p></li><li><p>DENALI THERAPEUTICS INC: LONG-TERM SAFETY DATA  DEMONSTRATE THAT TIVIDENOFUSP ALFA WAS GENERALLY WELL TOLERATED</p></li></ul><p>Source text: <span>ID:nGNX21hgts</span></p><p>Further company coverage: <span>DNLI.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nFWN3OX1D5:1","article_id":"2509206746","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2509206746","pubTimestamp":1738860332,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Denali Therapeutics Announces Primary Analysis & Long-Term Follow-Up Of Phase 1/2 Study In Hunter Syndrome With Tividenofusp AlfaFeb 6 (Reuters) - Denali Therapeutics Inc DNLI.O:DENALI THERAPEUT","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","DNLI":"Denali Therapeutics Inc.","BK4139":"生物科技","BK4548":"巴美列捷福持仓"},"translate_title":"简介-Denali Therapeutics宣布使用Tividenofusp Alfa治疗亨特综合征1/2期研究的主要分析和长期随访","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DNLI":0.9},"content_text":"BRIEF-Denali Therapeutics Announces Primary Analysis & Long-Term Follow-Up Of Phase 1/2 Study In Hunter Syndrome With Tividenofusp AlfaFeb 6 (Reuters) - Denali Therapeutics Inc DNLI.O:DENALI THERAPEUTICS ANNOUNCES PRIMARY ANALYSIS AND LONG-TERM FOLLOW-UP OF PHASE 1/2 STUDY IN HUNTER SYNDROME (MPS II) WITH TIVIDENOFUSP ALFADENALI THERAPEUTICS: TIVIDENOFUSP ALFA REGULATORY SUBMISSION FOR ACCELERATED APPROVAL PLANNED FOR EARLY 2025DENALI THERAPEUTICS: TIVIDENOFUSP ALFA U.S. LAUNCH PREPARATION ONGOING TO DELIVER TIVIDENOFUSP ALFA TO FAMILIES WITH MPS II IN LATE 2025 OR EARLY 2026DENALI THERAPEUTICS INC: LONG-TERM SAFETY DATA  DEMONSTRATE THAT TIVIDENOFUSP ALFA WAS GENERALLY WELL TOLERATEDSource text: ID:nGNX21hgtsFurther company coverage: DNLI.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1}}}